Chao‐Wei Hsu

1.4k total citations
25 papers, 972 citations indexed

About

Chao‐Wei Hsu is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Chao‐Wei Hsu has authored 25 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 15 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Chao‐Wei Hsu's work include Liver Disease Diagnosis and Treatment (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Hepatitis C virus research (8 papers). Chao‐Wei Hsu is often cited by papers focused on Liver Disease Diagnosis and Treatment (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (8 papers) and Hepatitis C virus research (8 papers). Chao‐Wei Hsu collaborates with scholars based in Taiwan, United States and Philippines. Chao‐Wei Hsu's co-authors include Yi‐Cheng Chen, Chen‐Chun Lin, Shi‐Ming Lin, Chun‐Jung Lin, Chau‐Ting Yeh, Shi‐Ming Lin, Chun‐Jung Lin, Deng‐Yn Lin, Dar‐In Tai and Yun‐Fan Liaw and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Chao‐Wei Hsu

22 papers receiving 950 citations

Peers

Chao‐Wei Hsu

HEPAT

EPIDE

SURGE

M. Giovanelli Italy

Miho Nakao Japan

Osakuni Morimoto Japan

Chao-Jung Tsao Taiwan

Yasuro Niwa Japan

Young-Hwa Chung South Korea

Eriko Goto Japan

Naoya Kanogawa Japan

Annalisa Ardiri Italy

Ye Jin Ha South Korea

M. Giovanelli Italy

Chao‐Wei Hsu

543 ×0.7

HEPAT

293 ×0.5

EPIDE

173 ×1.1

141 ×0.9

287 ×2.0

SURGE

Citations per year, relative to Chao‐Wei Hsu Chao‐Wei Hsu (= 1×) peers M. Giovanelli

Countries citing papers authored by Chao‐Wei Hsu

Since Specialization

Citations

This map shows the geographic impact of Chao‐Wei Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chao‐Wei Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chao‐Wei Hsu more than expected).

Fields of papers citing papers by Chao‐Wei Hsu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chao‐Wei Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chao‐Wei Hsu. The network helps show where Chao‐Wei Hsu may publish in the future.

Co-authorship network of co-authors of Chao‐Wei Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Chao‐Wei Hsu. A scholar is included among the top collaborators of Chao‐Wei Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chao‐Wei Hsu. Chao‐Wei Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lin, Yang-Hsiang, Yu‐De Chu, Kwang‐Huei Lin, et al.. (2025). HBx mutant-regulated RPL13AP25 mediates suboptimal virological response to entecavir and HCC progression. Cancer Cell International. 25(1). 223–223. 1 indexed citations

Huang, Chien‐Hao, Chung‐Li Wang, Victor Chien‐Chia Wu, et al.. (2025). Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study. Annals of Medicine. 57(1). 2573146–2573146.

Chu, Yu‐De, Chao‐Wei Hsu, P. P. K. Ho, et al.. (2024). Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy. Journal of Gastroenterology and Hepatology. 40(1). 265–273.

Hsu, Chao‐Wei, Wei‐Ting Chen, Sien‐Sing Yang, et al.. (2023). Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype. Cancer Science. 115(2). 564–574. 12 indexed citations

Lin, Chen‐Chun, Tsung‐Han Wu, Wei Teng, et al.. (2023). Adding nutritional status to the original BCLC stage improves mortality prediction for hepatocellular carcinoma patients in HBV-endemic regions.. PubMed. 13(8). 3618–3628. 4 indexed citations

Wang, Teh‐Wei, et al.. (2020). SIRT1-Mediated Expression of CD24 and Epigenetic Suppression of Novel Tumor Suppressor miR-1185-1 Increases Colorectal Cancer Stemness. Cancer Research. 80(23). 5257–5269. 36 indexed citations

Lin, Chen‐Chun, Chao‐Wei Hsu, Yi‐Cheng Chen, et al.. (2019). A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. The Pharmacogenomics Journal. 20(1). 57–68. 10 indexed citations

Komorowski, Andrzej L., et al.. (2018). AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients. Neoplasma. 65(3). 455–460. 8 indexed citations

Lin, Wey‐Ran, Chao‐Wei Hsu, Yi‐Cheng Chen, et al.. (2017). Combinations of single nucleotide polymorphisms WWOX‐rs13338697, GALNT14‐rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology. 14(2). e54–e63. 10 indexed citations

10.

Huang, Ya‐Hui, Kung‐Hao Liang, Rong‐Nan Chien, et al.. (2017). A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients. Scientific Reports. 7(1). 523–523. 32 indexed citations

11.

Liang, Kung‐Hao, Chih‐Lang Lin, Chao‐Wei Hsu, et al.. (2016). UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. Scientific Reports. 6(1). 34088–34088. 4 indexed citations

12.

Lin, Wey‐Ran, Chao‐Wei Hsu, Ming‐Ling Chang, et al.. (2014). GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. Molecular and Clinical Oncology. 2(4). 630–640. 16 indexed citations

13.

Huang, Ya‐Hui, Kwang‐Huei Lin, Hua‐Chien Chen, et al.. (2012). Identification of Postoperative Prognostic MicroRNA Predictors in Hepatocellular Carcinoma. PLoS ONE. 7(5). e37188–e37188. 77 indexed citations

14.

Leung, Nancy, Chung‐Kang Peng, Hie‐Won Hann, et al.. (2008). Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B. Hepatology. 49(1). 72–79. 146 indexed citations

15.

Lin, Chen‐Chun, Chun‐Jung Lin, Wei‐Ting Chen, et al.. (2007). Treatment of Hepatocellular Carcinoma Using Internally Cooled Electrodes. Oncology. 72(Suppl. 1). 76–82. 7 indexed citations

16.

Lin, Chen‐Chun, Chun‐Jung Lin, Chao‐Wei Hsu, et al.. (2007). Fine‐needle aspiration cytology to distinguish dysplasia from hepatocellular carcinoma with different grades. Journal of Gastroenterology and Hepatology. 23(7pt2). e146–52. 10 indexed citations

17.

Yeh, Chau‐Ting, Chao‐Wei Hsu, Ming‐Ling Chang, et al.. (2006). A Novel Ex Vivo Assay of Interferon‐Based Suppression, to Predict the Outcome of Antiviral Therapy for Hepatitis C. The Journal of Infectious Diseases. 193(10). 1365–1370. 3 indexed citations

18.

Lin, Shi‐Ming, Chun‐Jung Lin, Chao‐Wei Hsu, et al.. (2004). Prospective randomized controlled study of interferon‐alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 100(2). 376–382. 106 indexed citations

19.

Lin, Shi‐Ming, Chun‐Jung Lin, Chen‐Chun Lin, Chao‐Wei Hsu, & Yi‐Cheng Chen. (2004). Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology. 127(6). 1714–1723. 439 indexed citations

20.

Hsu, Chao‐Wei, et al.. (2003). Colonic Actinomycosis Presenting as Diffuse Colitis and Protein-Losing Enteropathy. Gastrointestinal Endoscopy. 58(3). 448–451. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact